Episode Details
Back to Episodes
Bay Area based Nosis Bio is leveraging AI to get its gene silencers specifically to precise cell types - it recently announced a development candidate to tackle fibrosis
Published 1 year, 1 month ago
Description
Co-Founder & CEO Jim Martineau walks us through the platform and describes the importance of being cell type specific. The company utilized a combination of AI and high-throughput chemistry in the wet lab.